高危前列腺癌:以根治性手术为核心的综合治疗策略

袁建林; 秦军

doi:10.13201/j.issn.1001-1420.2014.09.001

高危前列腺癌:以根治性手术为核心的综合治疗策略

袁建林^,,
秦军

- 第四军医大学西京医院泌尿外科(西安, 710032)

详细信息

通讯作者: 袁建林,E-mail:jianliny@fmmu.edu.cn

中图分类号: R737.25

收稿日期: 2014-07-30

Radical surgery as the core of comprehensive strategy for the treatment of high-risk prostate cancer

YUAN Jianlin^,,
QIN Jun

- Department of Urology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, China

More Information

Corresponding author: YUAN Jianlin, E-mail: jianliny@fmmu.edu.cn

Received Date: 30 July 2014

摘要

摘要: 高危前列腺癌的生物学行为难以预测，目前仍然是前列腺癌治疗的难点。以根治性前列腺切除术为核心的综合治疗策略能够获得良好的治疗效果。术前对其危险因素进行分层评估，有利于筛选合适的患者进行个体化治疗，进一步改善患者的预后。
- 前列腺癌 /
- 高危 /
- 根治性手术 /
- 综合治疗
Abstract: The biological behavior of high-risk prostate cancer is difficult to predict, thus the treatment of prostate cancer is still needed to overcome. Radical prostatectomy as the core of comprehensive treatment strategies can obtain good therapeutic effect. The risk factors were stratified to preoperative evaluation in order to select the appropriate patients for individualized treatment and further improve the prognosis of the patients.
- prostate cancer /
- high-risk /
- radical surgery /
- comprehensive treatment

HTML全文

参考文献(24)

[1]	D'Amico V A, Whittington R, Malkowicz B S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer[J]. Jama, 1998, 280:969-974.
[2]	Scardino P. Update:NCCN prostate cancer Clinical Practice Guidelines[J]. J Natl Compr Canc Netw, 2005, 3(Suppl 1):S29-33.
[3]	Ward J F, Slezak J M, Blute M L, et al. Radical prostatectomy for clinically advanced (cT₃) prostate cancer since the advent of prostate-specific antigen testing:15-year outcome[J]. BJU Int, 2005, 95:751-756.
[4]	Hsu C Y,Joniau S,Oyen R,et al.Outcome of surgery for clinical unilateral T_3a prostate cancer:a single-institution experience[J].Eur Urol,2007,51:121-128.
[5]	Zelefsky M J, Eastham J A, Cronin A M, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer:a comparison of clinical cohorts adjusted for case mix[J]. J Clin Oncol, 2010, 28:1508-1513.
[6]	Boorjian S A, Karnes R J, Viterbo R, et al. Long-term survival after radical prostatectomy versus external beam radiotherapy for patients with high-risk prostate cancer[J]. Cancer, 2011, 117(13):2883-2891.
[7]	Joniau S G, Van Baelen A A, Hsu C Y, et al. Complications and functional results of surgery for locally advanced prostate cancer[J]. Adv Urol, 2012; 2012:706309.
[8]	Kenneth A. Iczkowski M. Scott Lucia. Frequency of positive surgical margin at prostatectomy and its effect on patient outcome[J]. Prostate Cancer, 2011; 2011:673021.
[9]	Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer[J]. BJU Int, 2006, 98:788-793.
[10]	Joslyn S A, Konety B R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer[J]. Urology, 2006, 68:121-125.
[11]	肖文军,叶定伟,姚旭东,等.前列腺癌根治术中盆腔淋巴结清扫的意义及并发症防治[J].中华泌尿外科杂志,2010,31:770-773.
[12]	Engel J D, Kao W W, Williams S B, et al. Oncologic outcome of robot-assisted laparoscopic prostatectomy in the high-risk setting[J]. J Endourol, 2010, 24(12):1963-1966.
[13]	Shelley DM, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J]. Cancer Treat Rev, 2009, 35 (1):9-17.
[14]	Scolieri M J, Ahman A, Resnick M I. Neoadjuvant hormonal ablative therapy before radical prostatectomy:a review. Is it indicated?[J]. J Urol, 2000, 164:1465-1472.
[15]	Messing M E, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer[J]. N Engl J Med, 1999, 341(24):1781-1788.
[16]	Messing M E, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatm ent in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J]. Lancet Oncol, 2006, 7:472-479.
[17]	Wirth P M, Weissbach L, Marx J F, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer[J]. Eur Urol, 2004, 45:267-270.
[18]	McLeod G D,Iversen P,See A W,et al.Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer[J].BJU Int,2006,97(2):247-254.
[19]	Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy:a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2005, 366:572-578.
[20]	Wiegel T, Bottke D, Steiner U, et al. Phase Ⅲ postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT₃ prostate cancer with postoperative undetectable prostate-specific antigen:ARO 96-02/AUO AP09/95[J]. J Clin Oncol, 2009, 27:2924-2930.
[21]	Thompson I M, Tangen C M, Paradelo J, et al. Adjuvant radiotherapy for pathological T₃N₀M₀ prostate cancer significantly reduces risk of metastases and improves survival:long-term follow-up of a randomized clinical trial[J]. J Urol, 2009, 181:956-962.
[22]	Kibel A S, Rosenbaum E, Kattan M W, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy:a multi-institutional pilot study[J]. J Urol, 2007, 177:l777-1781.
[23]	Febbo P G, Richie J P, George D J, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer[J]. Clin Cancer Res, 2005, 11:5233-5240.
[24]	Chi K N, Chin J L, Winquist E, et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer[J]. J Urol, 2008, 180:565-570.